Broadfin Capital Initiates New Positions In Corium International Inc (CORI), AMAG Pharmaceuticals Inc. (AMAG) and La Jolla Pharmaceutical Company (LJPC)

In three recent filings,  Kevin Kotler’s Broadfin Capital has revealed adding three companies: Corium International Inc (NASDAQ:CORI), AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) and La Jolla Pharmaceutical Company (NASDAQ:LJPCto its equity portfolio.

Kevin Kotler

A new filing with the Securities and Exchange Commission showed that Broadfin Capital currently owns 1.35 million shares of Corium International Inc (NASDAQ:CORI), representing 7.66% of common stock outstanding.

Corium International Inc (NASDAQ:CORI) is a commercial stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal pharmaceutical products. Earlier in March, the company filed a registration statement on Form S-1 with for a proposed initial public offering of its common stock and later it priced its IPO of 6.50 million shares of common stock at a price to the public of $8.00 per share. The underwriters have been granted a 30-day option to purchase up to 975,000 additional shares of common stock at the IPO price.

In AMAG Pharmaceuticals Inc. (NASDAQ:AMAG), Broadfin Capital owns 1.43 million shares, the stake amasses 6.55% of the common stock. AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) is a specialty pharmaceutical company that markets Feraheme (ferumoxytol) Injection and MuGard Mucoadhesive Oral Wound Rinse in the United States.

Last month, Jacob Gottlieb’s Visium Asset Management disclosed initiating a 1.6 million position in AMAG Pharmaceuticals Inc. (NASDAQ:AMAG). Adage Capital Management, managed by Phill Gross and Robert Atchinson, held 3.80 million shares of the company at the end of 2013.

In another filing, Broadfin Capital disclosed owning a 5.37% passive stake in La Jolla Pharmaceutical Company (NASDAQ:LJPC). The new position contains around 389,900 common stock shares. La Jolla Pharmaceutical Company (NASDAQ:LJPC) is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer.

Earlier this month, the fund revealed a reduced stake in MELA Sciences, Inc (NASDAQ:MELA), owning a total of 9.1 million shares, equal to almost 10% of the common stock, down from over 16% held earlier.

Disclosure: none

Recommended Reading:

Broadfin Capital Initiates Stake in Pernix Therapeutics (PTX)

Kevin Kotler’s Broadfin Capital Initiates Stake in Eleven Biotherapeutics (EBIO) Following Its IPO

Broadfin Capital Initiates a Stake in Retrophin Inc (RTRX) Following Its Listing on NASDAQ

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

All In: The 7 Richest Poker Players in the World

Abracadabra: The 10 Best Magicians in the World

The 10 Richest Asian Countries in the World in 2014

Eyes in the Sky: 10 Things You Need to Know About Drones

Rising Stars: The 6 Best Silicon Valley Startups

Military Muscle: The 5 Most Advanced Armies in South America

All that Glitters: The 7 Most Luxurious Jewelry Brands in the World

5 Things You Didn’t Know About ISIS but Should

Empowering Your Money: The 5 Best Energy Stocks to Invest In

The 11 Best Android Apps You Can’t Get on iOS

The 10 Most Important International Conflicts in 2014

Mood Enhancers: The 20 Most Uplifting Songs of all Time

Lover Beware: The 8 Countries that Cheat the Most

Breath of Fresh Air: The 25 Countries with the Best Air Quality on the Planet

Singles Beware: The 8 Worst Mistakes Made on First Dates

Healthy and Happy: The 10 Countries with Lowest Healthcare Costs

The 6 Best Company Team Building Activities to Build Workplace Camaraderie

Ships Ahoy: The 10 Busiest Shipping Ports in the World

10 Productivity Tips to Save You Time and Help You Do More With Less

Grab a Bite: The Most Popular Fast Food Restaurants in America

Friday Night Thirst: The 10 Most Popular Cocktails in the World

The 6 Greatest Unsolved Mysteries We May Never Figure Out

7 Useless Products You Never Should’ve Bought

The 5 Reasons Why You’re Single and Miserable

The 7 Most Addictive Foods in the World We Can’t Stop Eating (Even Though We Should)

5 Amazing Places You Can Swim with Dolphins

The Top 7 Most Livable Countries In The World

The 10 Most Expensive Baseball Cards Ever Pulled From A Pack

The 5 Easiest Second Languages to Learn for English Speakers

Silver Spoon: The 6 Richest Families in the World

The 20 Countries with the Largest Prison Populations in the World

The Top 10 Richest Actors in the World

The 10 Best Airline Stocks to Invest In Before They Fly Too High

Burger Kings: The 10 Most Expensive Burgers in the World

The 10 Most Ethnically Diverse Countries in the World

The 10 Most Exclusive Credit Cards in the World

The 10 Most Expensive Cruise Ships in the World

The 10 Fastest Supercomputers in the World

The 10 Best Countries for Doing Business 2015

6 Most Expensive Fruits In The World

10 Worst Airlines in the World

The 10 Biggest Tax Havens in the World to Stash Your Money

The 15 Most Murderous Countries in the World

10 Largest Colleges in the World: Bigger Isn’t Always Better

Comedians in Cars Getting Coffee: The 6 Comedians Seinfeld Needs to Interview

Easy Money: The 10 Most Successful Investors in the World Today

The 10 Most Deadly Diseases in the World Today

The 5 Most Expensive Luxury Motorhomes in the World

20 Largest Stock Exchanges in the World

6 Richest Painters In The World 2014

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!